Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zagotenemab in Early Symptomatic Alzheimer's Disease
NCT03518073Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2018
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of zagotenemab in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Apr 2018; status: completed.
02
Drugs
zagotenemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03518073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03518073.